VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
IDXX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
IDXXIDEXX Laboratories, Inc.
$564.98$44.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

IDXX logoIDEXX Laboratories, Inc.(IDXX)Earnings, Financials & Key Ratios

IDXX•NASDAQ
$564.98
43.2× P/E·Price updated Jul 6, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryFood, Water and Veterinary Diagnostics
AboutIDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.Show more
  • Revenue$4.3B+10.4%
  • EBITDA$1.47B+16.5%
  • Net Income$1.06B+19.3%
  • EPS (Diluted)13.08+22.6%
  • Gross Margin61.8%+1.2%
  • EBITDA Margin34.08%+5.5%
  • Operating Margin31.6%+9.2%
  • Net Margin24.62%+8.1%
  • ROE66.2%+14.8%

IDXX Price & Volume

IDEXX Laboratories, Inc. (IDXX) stock price & volume — 10-year historical chart

Loading chart...

Accelerating Revenue Growth Amidst Margin Resilience

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Accelerating
Profitability:Strong
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Veterinary labor supply constraints

Key Thesis Takeaways

  • IDEXX Laboratories demonstrates a compelling growth trajectory, evidenced by revenue expansion accelerating from 3.6% in 2025Q1 to 14.3% by 2026Q1, supported by a dominant position in the veterinary diagnostics market.
  • While the company maintains strong pricing power with gross margins consistently exceeding 60%, investors should monitor the volatility in cash conversion efficiency and the potential impact of labor supply constraints on long-term operational scaling.
  • The firm's aggressive capital allocation strategy, highlighted by quarterly buybacks reaching $400.9 million in 2025Q1, underscores a commitment to shareholder returns that warrants careful balancing against the observed compression in liquidity ratios.

Verdict Logic

while the company exhibits robust top-line growth of 14.3% as of 2026Q1, the current P/E ratio of 42.16 suggests a premium valuation that may already price in significant future operational success.

IDXX Growth Metrics

IDEXX Laboratories, Inc. (IDXX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years10.39%
5 Years9.72%
3 Years8.52%
TTM13.08%

Profit CAGR

10 Years18.62%
5 Years12.74%
3 Years15.98%
TTM22.38%

EPS CAGR

10 Years20.36%
5 Years14.28%
3 Years17.66%
TTM25.32%

Return on Capital

10 Years57.6%
5 Years56.03%
3 Years56.22%
Last Year61.44%

IDXX Recent Earnings

IDEXX Laboratories, Inc. (IDXX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026
Metric
Actual
Est
EPS
$3.47+1.8%
$3.41
Rev
$1.1B+2.0%
$1.1B
Q1 2026
Feb 2, 2026
Metric
Actual
Est
EPS
$3.08+5.1%
$2.93
Rev
$1.1B+1.7%
$1.1B
Q4 2025
Nov 3, 2025
Metric
Actual
Est
EPS
$3.40+8.3%
$3.14
Rev
$1.1B+3.0%
$1.1B
Q3 2025
Aug 4, 2025
Metric
Actual
Est
EPS
$3.63+10.7%
$3.28
Rev
$1.1B+4.4%
$1.1B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 5, 2026
$3.47vs $3.41+1.8%
$1.1Bvs $1.1B+2.0%
Q1 2026Feb 2, 2026
$3.08vs $2.93+5.1%
$1.1Bvs $1.1B+1.7%
Q4 2025Nov 3, 2025
$3.40vs $3.14+8.3%
$1.1Bvs $1.1B+3.0%
Q3 2025Aug 4, 2025
$3.63vs $3.28+10.7%
$1.1Bvs $1.1B+4.4%
Based on last 12 quarters of dataView full earnings history →

Latest IDXX News

Recent stock market news and headlines for IDEXX Laboratories, Inc. (IDXX)

Business Wire·5 days ago
IDEXX Laboratories to Release 2026 Second Quarter Financial Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tuesday, August 4, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2026 Earnings Snapshot through a link on the IDEXX websi.

Zacks Investment Research·6 days ago
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research·Jun 29, 2026
Is the Options Market Predicting a Spike in IDEXX Laboratories Stock?

Investors need to pay close attention to IDXX stock based on the movements in the options market lately.

GuruFocus·Jun 17, 2026
IDEXX Laboratories Inc (IDXX) Stock Down 4.7% -- Now Undervalued? GF Score: 96/100

On June 17, 2026, IDEXX Laboratories Inc (IDXX) shares fell 4.7% to $546.09. The stock's current price is within a 52-week range of $506.91 to $769.98, reflecti

Peers Comparison

Key metrics vs top competitors for IDEXX Laboratories, Inc. (IDXX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
IDXX logoIDXXIDEXX Laboratories, Inc.Current
$564.98$44.87B43.1910.42%24.62%66.2%—
ZTS logoZTSZoetis Inc.
$75.42$31.62B12.532.28%27.79%62.41%—
HSIC logoHSICHenry Schein, Inc.
$86.62$9.87B26.494.03%2.95%8.14%—
ELAN logoELANElanco Animal Health Incorporated
$25.13$12.55B-53.476.22%-4.95%-3.64%—
ANIP logoANIPANI Pharmaceuticals, Inc.
$85.05$1.93B25.6243.78%9.71%17.32%—
NEOG logoNEOGNeogen Corporation
$9.51$2.07B-1.89-3.2%-69.93%-29%—

Compare IDXX vs Peers

IDEXX Laboratories, Inc. (IDXX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ZTS

Most directly comparable listed peer for IDXX.

Scale Benchmark

vs TMO

Larger-name benchmark to compare IDXX against a more recognizable public peer.

Peer Set

Compare Top 5

vs ZTS, HSIC, ELAN, ANIP

IDXX SEC Filings & Documents

IDEXX Laboratories, Inc. (IDXX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 5, 2026·SEC

Material company update

Mar 26, 2026·SEC

Material company update

Feb 13, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 20, 2026·SEC

FY 2025

Feb 21, 2025·SEC

FY 2024

Feb 22, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 5, 2026·SEC

FY 2025

Nov 3, 2025·SEC

FY 2025

Aug 4, 2025·SEC

Get notified when IDXX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

IDXX Frequently Asked Questions

IDEXX Laboratories, Inc. (IDXX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is IDEXX Laboratories, Inc.'s revenue?

IDEXX Laboratories, Inc. (IDXX) reported $4.45B in revenue for fiscal year 2025. This represents a 1561% increase from $267.7M in 1996.

How fast is IDEXX Laboratories, Inc. growing?

IDEXX Laboratories, Inc. (IDXX) grew revenue by 10.4% over the past year. This is steady growth.

Is IDXX profitable?

Yes, IDEXX Laboratories, Inc. (IDXX) is profitable, generating $1.10B in net income for fiscal year 2025 (24.6% net margin).

Dividend & Returns
What is IDXX's return on equity?

IDEXX Laboratories, Inc. (IDXX) has a return on equity (ROE) of 66.2%. This is excellent, indicating efficient use of shareholder capital.

What is IDEXX Laboratories, Inc.'s free cash flow?

IDEXX Laboratories, Inc. (IDXX) generated $845.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in IDXX back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →